(MedPage Today) — LAS VEGAS — GLP-1-based therapies may offer benefits in inflammatory bowel disease (IBD) that extend beyond their metabolic indication, according to two poster presentations at the Crohn’s & Colitis Congress.
In a large…
Source link : https://www.medpagetoday.com/meetingcoverage/ccc/119572
Author :
Publish date : 2026-01-25 19:15:00
Copyright for syndicated content belongs to the linked Source.
